J&J Settles Pa. Risperdal Lawsuit On Opening Day Of Trial

Law360, Philadelphia (September 10, 2012, 6:39 PM EDT) -- The morning his trial against Ortho-McNeil-Janssen Pharmaceuticals Inc. was set to begin, a 21-year-old Miami man on Monday accepted a settlement putting to rest allegations that the Johnson & Johnson subsidiary’s antipsychotic drug Risperdal caused serious changes to his endocrine and reproductive systems.

Aron Banks, who sued the drugmaker in the Philadelphia Court of Common Pleas in 2010, accepted the settlement shortly before open arguments in the trial were set to begin, according to Brian McCormick, an attorney with Sheller PC representing the plaintiff.

“Mr. Banks...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.